Show simple item record

dc.contributor.authorCarden, CP
dc.contributor.authorSarker, D
dc.contributor.authorPostel-Vinay, S
dc.contributor.authorYap, TA
dc.contributor.authorAttard, G
dc.contributor.authorBanerji, U
dc.contributor.authorGarrett, MD
dc.contributor.authorThomas, GV
dc.contributor.authorWorkman, P
dc.contributor.authorKaye, SB
dc.contributor.authorde Bono, JS
dc.date.accessioned2018-06-28T13:22:08Z
dc.date.issued2010-02
dc.identifier.citationDrug discovery today, 2010, 15 (3-4), pp. 88 - 97
dc.identifier.issn1359-6446
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1964
dc.identifier.eissn1878-5832
dc.identifier.doi10.1016/j.drudis.2009.11.006
dc.description.abstractAnticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.
dc.formatPrint-Electronic
dc.format.extent88 - 97
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectAntineoplastic Agents
dc.subjectDrug Approval
dc.subjectPharmacogenetics
dc.subjectModels, Biological
dc.subjectPatient Selection
dc.subjectClinical Trials, Phase I as Topic
dc.subjectBiomarkers, Pharmacological
dc.subjectDrug Discovery
dc.titleCan molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
dc.typeJournal Article
dcterms.dateAccepted2009-11-25
rioxxterms.versionofrecord10.1016/j.drudis.2009.11.006
rioxxterms.licenseref.startdate2010-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfDrug discovery today
pubs.issue3-4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cell Cycle Control (including GCLP Biomarker Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cell Cycle Control (including GCLP Biomarker Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.publication-statusPublished
pubs.volume15
pubs.embargo.termsNot known
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamCell Cycle Control (including GCLP Biomarker Group)en_US
icr.researchteamMedicine Drug Development Unit (Kaye)en_US
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorGarrett, Michelle Dawnen
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorBanerji, Udaien
dc.contributor.icrauthorWorkman, Paulen
dc.contributor.icrauthorKaye, Stanley Bernarden
dc.contributor.icrauthorAttard, Gerhardten
dc.contributor.icrauthorYap, Timothyen
dc.contributor.icrauthorTurner, Lydiaen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record